NCT00287716View on ClinicalTrials.gov

Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

PHASE3CompletedINTERVENTIONAL
Enrollment

435

Participants

Timeline

Start Date

July 14, 2006

Primary Completion Date

November 10, 2008

Study Completion Date

November 10, 2008

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Pirfenidone

1197 or 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.

DRUG

Placebo

Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.

Trial Locations (1)

94005

InterMune, Inc., Brisbane

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY